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A Randomized Trial of Intravenous Heparin in 12
(Anisoylated Plasminogen Streptokinas
Complex) in Nuae Myocardial Infarction : The Duke
Clinical Cardiology Study (_1J_CCS) I
Objectives . We designed a randomized trial to evaluate the
effects of heparin administration in conjunction with anistreplase
(anisoylated plasminogen streptokinase activator complex
[AFSACD on arterial patency and clinical end points .
Background. The role of conjunctive intravenous heparin
therapy with APSAC has not been tested despite the recommen-
dations that intravenous heparin should be used .
Methods Four hours after APSAC administration, 2,50 patients
with acute myocardial infarction were randomly assigned to receive
325 mg of either aspirin alone or aspirin and a continuous infusion of
hemdn (15 IU&g boody weight per h) . Clinical ischemic events and
bleeding complications were monitored . On hospital day 5, coronary
arteriography and left ventriculography were performed.
Results . The primary end point of the trial (the combined
outcome of death, reinfarction, recurrent ischemia and occlusion of
the infarct-related artery) occurred in 42% of the heparin-treated
group versus 43% of the group treated without heparin (p = 0 .94).
Cardiologists in the United States routinely use heparin as
conjunctive therapy after thrombolysis in the setting of acute
myocardial infarction (1) . Three lines of evidence support
From the Division of Cardiology, Department of Medicine and Division of
Biometry, Department of Community and Family Medicine, Duke University
Medical Center . Durham, North Carolina
. This study was supported by
Research Grants HS-05635 and HS-06503 from the Agency for Health Care
Policy and Research . Rockville
. Maryland and grams from the Robert Wood
Johnson Foundation, Princeton, New Jersey
; the DUCCS Reseal Founda-
tion, Durham, North Carolina
; and Upjohn/Smithkfine Beecham Pharmaceu-
ticals, Philadelphia, Pennsylvania .
*See Appendix for a complete list of the investigators and personnel for
DUCCS .
Manuscript received January 25, 1993
; revised manuscript received
August 2, 1993, accepted August 4, 1993 .
Address for
correspondence: Dr. Christopher M . O'Connor, Duke Uni-
versity Medical Center, Box 3356, Durham, North Carolina 27710
.
01994 by the American College of Cardiology
J
11action With
Activator
University
CHRISTOPHER M . O'CONNOR, MD, FACC, RODERICK MEESE, MD, FACC,
ROBERT CARNEY, MD, FACC, JACK SMITH, MD, FACC, ERIC CONN, MD, FACC,
JOHN BURKS, MD, FACC, CARL HARTMAN, MD, FACC, STEVE ROARK, MD, FACC,
NEAL SHADOFF, MD, FACC, MAURICE HEARD III, MD, FACC, BRANT LITTLER, MD,
GARY COLLINS, MD, FACC, FRANK NAVETTA, MD, FACC, JEFF LEIMBERGER, PHD,
KERRY LEE, PHD, ROBERT M . CALIFF, MD, FACC, FOR THE DUCCS GROUP*
Durham, North Carolina
11
A patent artery was present in 80% of the patients
treated with heparin and in 73% of those treated without heparin
(p = 0.26). Left ventricular function, as measured by ejection
fraction, was well preserved in both groups (52% vs . 50.5%,
respectively, p = 0.29). The overall bleeding rate was higher in
patients with (32%) than without (17 .2%) heparin (p = 0.006) .
Conclusions. Weight-adjusted intravenous heparin therapy
after APSAC in acute myocardial infarction does not reduce the
combined incidence of death, reinfarction, recurrent ischemia and
xcluslon of the infarct-related artery . Furthermore, withholding
intravenous heparin therapy is associated with a 46% reduction in
bleeding complications . Our findings do not support the addition
of intravenous heparin after APSAC therapy, as currently recom-
mended, and suggest that a strategy of withholding heparin is
simpler and safer and does not place the patient at increased risk
for ischemic complications after myocardial infarction .
(J Am Coll Cardiol 1994,23 :11-8)
this pract, ce . 1) Subcutaneous heparin reduces the risk of
in-hospital death, reinfarction and other thromboembolic
events when given with streptokinase and recombinant
tissue-type plasminogen activator (rt-PA) (2-6) . 2) Arterial
patency is maintained more completely when intravenous
heparin is administered with rt-PA (7-9) . Unfortunately,
there is no convincing evidence for better clinical outcome,
although ongoing studies are addressing this issue (10-14) .
3) Heparin suppresses markers of ongoing thrombosis that
are increased early after thrombolytic therapy regardless of
the agent used (15) .
APSAC (anisoylated plasminogen streptokinase activator
complex), or anistreplase, is a thrombolytic agent with a
marked effect on the coagulation system, as evidenced by
profound fibrinogen depletion and increased fibrinogen deg-
radation products, with their associated antiplatelet and
0735-1097194IS6 .00
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antithrombin effects (16-25) . Initial studies, including a large
mortality trial that proved the clinical benefits of anis-
treplase, the APSAC Intervention Mortality Study (AIMS)
(26,27), used intravenous heparin starting 6 h after the
administration of APSAC despite a lack of evidence that
heparin either improved clinical outcome or decreased cor-
onary artery reocclusion . Moreover, the risk of bleeding
secondary to heparin was not assessed carefully . Because
the profound systemic lytic state might make heparin use
with its attendant risks and complexity of administration
unnecessary, we designed a randomized trial to evaluate the
effects of heparin in conjunction with APSAC on arterial
patency and clinical end points.
Methods
Study patients. Between August 1990 and duly 1991, 250
patients presenting within 12 h of the onset of symptoms
suggestive of an acute myocardial infarction were enrolled in
this randomized trial. Patients <86 years of age were con-
sidered eligible if there was ST segment elevation of at least
0.1 mV in two or more contiguous electrocardiographic
(ECG) leads. The inclusion of elderly patients and patients
presenting relatively late after symptom onset was based on
recent data indicating the benefit of thrombolysis in these
patients (28) .
Patients were excluded for the following reasons: need
for heparin or long-term warfarin therapy ; contraindication
to heparin therapy; history of significant bleeding diathesis ;
history of gastrointestinal and genitourinary bleeding within
the previous 4 weeks; history of cerebrovascular disease ;
major surgery or biopsy within the previous 14 days ; cardio-
pulmonary resuscitation lasting >10 min within the previous
2 weeks; severe trauma within the previous 6 months ;
intracranial lesions ; uncontrolled hypertension, with a dia-
stolic blood pressure >110 mm Hg or a systolic blood
pressure > 180 mm Hg after treatment for pain and confirmed
by two repeated measurements ; cardiogenic shock; comor-
bid illness likely to limit life expectancy within the next
2 years ; previous treatment with streptokinase or APSAC ;
diabetic hemorrhagic retinopathy ; pregnancy or childbearing
potential; inability to give informed consent . The expanded
criteria of advanced age up to 85 years, presentation within
12 h, previous coronary artery bypass surgery, cardiopulmo-
nary resuscitation lasting <10 min within the previous
2 weeks or mild to moderate hypertension allowed the
inclusion of patients traditionally excluded in trials of throm-
bolytic therapy. All patients provided written informed
consent. Institutional Review Board approval was required
before initiation of the protocol .
Study design. Patients who met criteria for entry into the
protocol were randomized by telephone to receive heparin
or no heparin . Permuted block randomization was used with
a block size of eight . Because of concern about the efficacy
of heparin in late-presenting patients, two strata were de-
fined at the time of randomization : presentation within 6 h
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and between 6 and 12 h . Patients received 30 U of intrave-
nous APSAC (anistreplase [Eminasel) for 2 to 5 min . All
patients received 325 mg of aspirin orally (first dose
preferably chewed) on presentation and daily thereafter .
Concurrent beta-adrenergic blocking agent and nitrate ther-
apy were encouraged . Patients randomized to heparin ther-
apy received an infusion until 18 to 24 h before the elective
cardiac catheterization on day 5 .
The hospital course was monitored carefully for clinical
outcome and bleeding complications . Coronary angiography
was performed earlier than the 5th hospital day if clinically
indicated because of recurrent isehemia or reinfarction .
Cardiac catheter° lion . On achieving vascular access, a
3,000-U heparin bolus was administered to all patients .
Biplane left ventriculography was performed first, followed
by angiography of the noninfarct-related arteries with paired
orthogonal views . Next, the infarct-related artery was in-
jected, and the Thrombolysis in Myocardial Infarction
(TIMI) flow grade was scored on the initial injection (29) .
Management of the patient after the initial injection into the
infarct-related artery was left to the discretion of the inves-
tigator .
All cardiac catheterization angiograms were reviewed
and analyzed at the angiographic core laboratory . Angio-
grams were interpreted without knowledge of the treatment
assignment. The primary angiographic end point was the
assessment of patency of the infarct-related coronary artery .
Patency was defined as TIMI flow grade 2 or 3, and occlu-
sion was defined as TIMI flow grade 0 or 1 (29) . Angio-
graphic core laboratory readings were used in the final
analysis . The variables interpreted visually included percent
lumen diameter narrowing at the infarct lesion location and
TIM[ flow grade into the coronary bed distal to the irfarct
site. The infarct-related artery segments remote to the in-
farct lesion and noninfarct-related arteries were graded
visually as to the presence or absence of significant stenusis .
The aforementioned assessments were repeated after any
mechanical intervention at the infarct site . Global left ven-
tricular ejection fraction and regional wall motion were
determined using the centerline regional wall motion analy-
sis method (30,31) .
And coagulation . For patients who were randomized to
receive heparin (CUSP, heparin, Upjohn Company), an infu-
sion of 15 lUIkg body weight per h of heparin was started 4 h
after the administration of APSAC and continued for 24 h .
Adjustments were allowed in the 1st 24 h only if the
activated partial thromboplastin time (aPTT) was <50 s .
After the 1st 24 h of heparin administration, heparin was
monitored by the aPTI' and adjusted to maintain anticoagu-
lation between 50 and 90 s using weight-adjusted methods .
Heparin was discontinued 18 to 24 h before day 5 of cardiac
catheterization to minimize access site bleeding complica-
tions . To carefully monitor the degree of anticoagulation, the
WIT was measured every 6 h for the 1st 24 h, then every
12 h.
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Management of bleeding complications. Recommenda-
tions for the management of bleeding complications were
standardized but ultimately left to the discretion of the
investigator. Transfusion with packed red blood cells was
withheld unless the following conditions were met, 1) docu-
mented hematocrit !525% in a patient who was stable hemo-
dynamically, and 2) hemodynamic instability not responsive
to crystalloid infusion, with clinical evidence of significant
blood loss regardless of measured hematocrit . If significant
hemorrhage occurred within 24 to 48 h after administration
of thrombolytic therapy, the standardized strategy, as de-
scribed previously by Sane et al . (32), was instituted .
Definitions . Important clinical outcomes were prospec-
tively defined . Stroke was defined as an acute neurologic
deficit resulting in death or lasting >24 h, which was
confirmed by a neurologist and a computed tomographic
scan of the head, nuclear magnetic resonance imaging or
autopsy . Reinfarction was defined as a second elevation in
serum cardiac enzyme. levels more than two times the
previous trough level after the 16th hour sample . If enzyme
levels were not available, typical symptoms and ECC
changes were required . Congestive heart failure was defined
as pulmonary edema on chest radiograph, rales more than
basilar or an
S3
gallop with the requirement of additional
diuretic therapy over pretreatment requirements . Recurrent
ischemia was symptomatic (chest, neck or arm ischemic
pain), with new ST segment changes, a deep T wave
inversion on the ECG, new hypotension, pulmonary edema
or a holosystolic murmur with symptoms of ischemia .
Bleeding complications were assessed using the Throm-
bolysis and Angioplasty in Myocardial Infarction (TAW)
bleeding criteria (33) . Life-threatening bleeding was defined
as an intracranial hemorrhage or internal bleeding (gastro-
intestinal, genitourinary, retroperitoneal or perivascular)
that catsed sustained hypotension (systolic blood pressure
<90 mm Hg for >1 h). Severe bleeding wa.- defined as
gastrointestinal, genitourinary, retroperitoneal or perivascu-
lar bleeding with >500 ml of observed blood loss requiring
blood transfusion to improve the clinical condition . Moder-
ate bleeding was defined as superficial gastrointestinal,
genitourinary, retroperitoneal or perivascular bleeding with
an observed blood loss of 250 to 500 ml without the require-
ment for blood transfusion other than to augment the hema
tocrit. Mild bleeding was defined as bleeding of no clinical
consequence, not requiring a transfusion and with <250 ml
of observed blood loss .
End points. The primary end point of the study was a
composite angiographic clinical assessment of coronary
occlusionlischemia. The patient's treatment was recorded as
a failure when angiographic coronary artery occlusion (TIM]
flow grade 0 or 1) (30), reinfarction, recurrent ischemia or
death occurred .
Three important secondary end points were defined be-
fore the trial began: 1) a composite clinical morbidity end
point that scored recurrent ischemia, congestive heart fail-
ure, reinfarction, stroke and death in rank order (12) ;
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Table t> Baseline Characteristics DF 11T, Two TreaImena Groups
Numbers in parentheses are interquartile ranges
. HP = blood pressure ;
HR = heart rate ; MI = myocardial infarction .
2) hemmrrhLgic events (major and minor) ; and 3) ejection
fraction (global and regional) .
Statistical analysis. All end points were analyzed using
the intention to treat principle. Because two enrolled pa-
tients did not have confirmation of acute myocardial infarc-
tion, a secondary analysis of patency included only patients
with a documented myocardial infarction and an infarct-
related artery that could be identified . Discrete baseline
variables were summarized as percents, whereas continuous
variables were summarized as medians with 25th and 75th
percentiles unless otherwise noted . Categoric outcome vari-
ables were compared between the treatment groups using
chi-square methods or the Fisher exact test with appropriate
confidence intervals constructed . Continuous efficacy and
safety variables were compared using the Wilcoxon rank-
sum test . The in-hospital morbidity index and hemorrhagic
scores were examined by ordinal logistic regression analysis .
Sample size . On the basis of reported studies evaluating
heparin, this trial was designed to be able to detect a
reduction of 20% in the primary end point (30% in the
treatment group vs. 50% in the control group) . Accordingly,
with an alpha level of 0 .05 and a power of 0 .8, a sample size
of 103 patients in each group was required . However, to
define treatment differences in both primary and secondary
end points with a greater degree of precision, the chosen
sample size was 250 patients .
Results
One hundred twenty-eight patients were randomized to
receive heparin and 122 patients to receive no heparin . Two
hundred thirty (92%) of the 250 patients were enrolled in the
first stratum (between 0 and 6 h of presentation) and 20
patients ia the second stratum . The baseline characteristics
and demographics of the patients (Table 1) were evenly
distributed between the treatment groups .
In patients assigned to the weight-adjusted intravenous
heparin strategy, the blood was well anticoagulated at 24 h .
The median aPTT at the 24-h point in the heparin group was
67 s versus 27 s in the no-heparin (p = 0 .001). At 24 h, 10%
of the patients assigned to receive heparin had an aPTT
Heparin
(a = 123)
No Heparin
in =1221
Age (yr) 62 (52-69) 61 (52-68)
>75 yr 9 11
Men (%) 77 77
Anterior Ml ( 17o) 36 4.1
Symptoms to treatment (h) 3 .2 (2 .2-43) 3 .0 (2 .2-4.3)
Baseline HR (beatsimin) 73 (62-85) 76 (64-86)
Systolic BP (mm Hg) 132 (117-150) 128 (112-143)
Diastolic BP (mm Hg) 80 (70-92) 80 (69-90)
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Table 2
. Perfusion Grades and Left Ventricular Function at Day 5
of Diagnostic Catheterization
Numbers in parentheses represent 95% confidence limits for the point
e
stimate . LV = left ventricular; TIM[ = Thrombolysis in Myocardial Infarc-
tion trial .
>114 s, and 10% had an aPTT <38 s. Only 10% of the
patients with no heparin had an >44 s at 24 h. By 48 h,
the majority of heparin-treated patients had aPTT measure-
ments in the desired range (88% vs . 18%, p = 0.0001) .
Thirteen (9.9%) of 122 patients randomized to receive no
heparin were treated with heparin for clinical indications, the
majority (9 of 13) because of recurrent ischemia or hemody-
namic instability .
Two hundred thirty-one (92%) of the 250 patients under-
went predischarge cardiac catheterization at a median of 4 .5
days. The angiographic outcomes are displayed in Table 2 .
The overall patency (TIM[ flow grade 2 or 3) at day 5 cardiac
catheterization was 77% . Eighty percent of patients in the
heparin group had a patent infarct-related artery versus 73%
in the no-heparin (p = 0 .26) . In the first stratum (presenta-
tion within 6 h) . the ratency was 79% in the heparin group
and 76% in the no-heparin group .
Clinical outcome is displayed in Tables 3 and 4. Although
Table 3
. Clinical Outcome
Numbers in parentheses represent 95% confidence limits for the point
estimate
. CHF = congestive heart failure
; M1= myocardial infarction .
Table 4. Revascularization Procedures
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CABG = coronary artery bypass grafting; PTCA = percutaneous trans-
luminal coronary angioplasty .
all differences were small and not statistically significant, the
trends were for fewer thromboembolic complications in the
patients treated without heparin . The overall incidences of
death, stroke and reinfarction were somewhat lower in this
treatment group. The requirement for invasive procedures
during the hospital stay was similar in both groups . Coronary
artery bypass grafting was performed in 15% of patients
treated with heparin and 13% of patients treated without
heparin, and percutaneous transluminal coronary angio-
plasty was performed in 32% and 41% of patients, respec-
tively, in the heparin and no-heparin groups (p = 0 .14) .
The primary end point of the trial (the combined inci-
dence of death, reinfarction, recurrent ischemia and occlu-
sion of the infarct-related artery) occurred in 42% of the
heparin group versus 43% in the no-heparin group (p = 0 .94) .
When recurrent ischemia, the "softest" end point, was
omitted from this analysis, there was still no difference
between the groups (28% in the heparin vs . 30% in the
no-heparin group) . No significant differences were found in
the key secondary end points of composite clinical events
(p = 0.46) or left ventricular function (Table 5) . Left ven-
tricular ejection fraction was well preserved in both groups
(52% vs . 50.5%, p = 0.29) .
The overall rate of bleeding complications of greater than
mild degree was higher in the heparin group (32%) than in the
no-heparin group (17 .2%) (p = 0.006) (Table 6). A sixfold
reduction in life-threatening bleeding complications was
observed in patients randomized to the no-heparin group
(0.8% vs . 4 .7%). The transfusion rate was 23% in the heparin
group and 16% in the no-heparin group (p = 0 .12) .
Table 5 . Composite Clinical End Point
*Rank order
: death, stroke, reinfarction, congestive heart failure (CHF)
or new pulmonary edema or recurrent ischemia and none of these
; p = 0 .46 .
Clinical
Rank*
Heparin (%)
(n = 128)
No Heparin (%)
(n = 122)
None 0
50 48
CHF or recurrent ischemia 1 35 41
Reinfarction
2 5 2
Stroke 3
2 0
Death
4 9
7
Heparin (%)
(n = 128)
No Heparin (%)
(n = 122)
CABG
Emergency 4 4
Urgent 4 2
Elective 7 7
Angioplasty
Emergency 14 14
Elective 18 27
Any revascularization (FT. CA or CABG) 43 54
Heparin (%)
(n = 117)
No Heparin (%)
(n = 114)
p
Value
TIMI flow grade
0
11(6-16)
15(7-21)
1
10(5-15) 12(6-18)
2
40-9) 8(3-13)
3 75(67-83) 65(57-73)
Patent infarct-related artery 80 (73-87) 73(65-81)
0.26
(TIMI flow grade 2 or 3)
Stratum 0-6 h to treatment
79(71-87) 75(60-84)
LV ejection fraction (%) 52(46-60) 50 .5 (43-59) 0.29
Heparin
(n = 128)
No
Heparin
(n = 122)
Death
By day 14 (%)
9(4-14)
7(2-12)
Age s75 yr (%)
7(3-11)
10-3)
Age >75 yr (%)
31 (23-39) 50(41-59)
Male (%)
4(1-7)
2(0-4)
Female (%)
27(.20-34) 18(11-25)
Stroke (%)
3(0-6) 0.8(0-2 .4)
Hemorrhagic (%)
1 .6(0-3 .8) 0
Nonhemorrhagic (%)
1
.6(0-3 .8)
0
.8(0-24)
Reinfarction (%)
7(3-11) 3(0-6)
Recurrent ischemia (%)
26(18-34) 24(16-32)
CHF (%)
30(22-38) 33(25-41)
Any of the five previous outrlmes (%)
52(43-61)
50(41-59)
Primary end point failure
nary occlusion,
42(33-51) 43(34-52)
recurrent ischemia, Ml -
path)
JACC Vol
. 23, No . I
January 1994 :11-9
Table 6. Bleeding Complications
Discussion
The most important finding of this study is that intrave-
nous heparin added to a regimen of 325 mg of aspirin failed
to reduce the combined incidence of recurrent ischemia,
reinfarction, death and occlusion of the infarct-related artery
after anistreplase therapy . Furthermore, the rate of signifi-
cant bleeding was 46% lower in patients randomized to
receive no heparin, and life-threatening bleeding was six
times lower in this group .
Baseline characteristics . The patients in this trial consti-
tuted a higher risk group than patients enrolled in previous
angiographic trials evaluating the role of heparin therapy
(7-11) . Patients with previous coronary artery bypass graft-
ing and prolonged cardiopulmonary resuscitation were not
excluded from the study and 10% of the patients were >75
years old, 25% were women, and 10% presented after 6 h of
symptoms. The high risk composition of the patient group
explains in part the high rate of bleeding and adverse clinical
events in the patients who received heparin and underscores
the importance of reduced bleeding in the patients with no
heparin .
Anticoaplation . Because subtherapeutic aPTT measure-
ments have been associated with recurrent ischemia after
administration of streptokinase and with low patency rates
after treatment with rt-PA (34-38), we chose a heparin
protocol that was adjusted to body weight and monitored
every 12 h after the 1st 24 h. We also chose a range of
anticoagulantt therapy that was higher (two to three times
control) than that of previous heparin angiographic trials .
The range of heparin anticoagulation most commonly de-
sired by our investigators who were polled before the study
was 50 to 90 s . Of importance, the majority of patients (88%)
randomized to receive heparin had an aPTT in this range
during the 1st 48 h compared with 18% of patients random-
ized to receive no heparin (p = 0 .0001) .
All patients who underwent protocol-mandated cardiac
catheterization in the absence of an urgent clinical indication
had the heparin administration stopped 18 to 24 h before
cardiac catheterization to avoid excessive access site bleed-
ing. The frequency of events in this time period was small
and not significantly different between the heparin (2 .41%)
and the no-heparin (2.3%) groups . These findings are similar
to the results of the National Heart Foundation of Australia
trial (11), in which there were no increased ischemic events
O'COINNOR ET AL
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after stopping heparin 24 h after the infusion of intravenous
rt-PA .
Paicacy . We found no significant difference in patency
between the two study groups, and the difference in patency
among those treated within 6 h of symptom onset was even
smaller (79% vs. 75%). Similarly, in patients treated with
APSAC and intravenous heparin, Meinertz et al .
ported a late (2-week) patency rate of 75%, and the patency
rate in the Angiographic Patency Study in Myocardial In-
farction (APSIM) study (38) at a median of 4 days was 77% .
Early angiographic data suggest patency rates of 60% to 75%
at 90 min and up to 907o at 24 to 48 h (39-41) .
Clinical events. The 14-day mortality rate of 8% com-
pares favorably with previously reported mortality rates of
APSAC-treated patients (41,42) and with that of the heparin
randomized mortality trials (2-4) . The mortality rate in this
trial is due at least in part to the higher risk patients in our
study: 10% of the patients were >75 years old, and they had
an associated 40% mortality rate compared with 4% in
younger patients . Elderly patients are known to have a
higher baseline risk of death, partly because of the greater
extent of their coronary artery disease and their propensity
to experience mechanical and bleeding complications (43).
The total stroke rate was 2% in this trial, which is
comparable to that of previous studies with careful follow-up
(44,45) . The rates of reinfarction and recurrent ischemia
tended to be higher in the heparin group but overall rates
were similar, as in previous studies (46) . There are several
potential reasons for these findings . 1) Statistical chance
must be considered given the small size of our study .
2) Patients randomized to receive heparin may experience
intraplaque hemorrhage, causing further instability of the
reperfused infarct-related artery and thus causing recurrent
ischemia and reinfarction . 3) Patients randomized to receive
heparin may actually have had a higher early patency rate
and thus a greater risk for experiencing reinfarction and
recurrent ischemia. This trend has been observed in several
other studies (7,8) (Coe J, personal communication, Novem-
ber 1992). 4) The procoagulant effects of heparin may
become important in the postthrombolytic setting . 5) Hepa-
rin may cause thrombocytopenia, which enhances platelet
agglutination .
Bleeding complications and left ventricular function .
Bleeding complications were carefully monitored and scored
using the previously discussed TAMI criteria (33) . Although
50% of the patients in the trial experienced a bleeding
complication, most cases were classified as mild . The overall
rate of bleeding events was similar to those in previous
thrombolytic trials with protocol angiography (7-11,33,
39,40,46-48). The Heparin-Aspirin Reperfusion Trial study
investigators (7) reported a lower rate of bleeding (12%) .
However, Bleich et a
l. (8) reported a similar bleeding rate .
The most common site of bleeding was at the access site
in the femoral region . Genitourinary (17%) and gastrointes-
tinal (5%) bleeding were also not infreque at
. ir.iracranial
hemorrhage occurred in two patients (1
.6%), both of whom
Type of Bleeding Episode
Heparin (%)
W= Im
No
Heparin
(n = 122) Value
Moderate 18 .8 10 .7
Severe 8 .6 5 .7
Life-threatening 4 .7 0.4
Total patients with bleeding episodes
(only most severe counted)
32 17 .2 0 .006
16
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received heparin therapy. Moderate, severe and life-
threatening hemorrhages were two times higher in the hep-
arin group than in the no-heparin group, which is consistent
with data from the Third International Study of Infarct
Survival (4) and Gruppo Italiano per to Studio della Soprav-
vivenza nell'Infarto Miocardico (2) studies . The blood trans-
fusion rate paralleled the bleeding rate and tended to be
lower in the no-heparin group .
Study limitations. Several design limitations of this study
should be considered . 1) Most important, the size of the trial
was not sufficient to detect small differences in perfusion or
clinical event rates . Before the study we believed that 200
patients would be adequate to detect a significant reduction
in recurrent ischemic events and infarct-related artery oc-
clusion on the basis of differences found in published reports
evaluating conjunctive heparin therapy with rt-PA (7-11) . To
have adequate power to detect a difference of the magnitude
that we observed (Table 2), > 1,500 patients with angiograms
would have L-en required . 2) Neither the patients nor the
medical staff members were unaware of the study treatment .
All efforts were made to reduce bias by keeping the angio-
graphic core laboratory unaware of the study treatment and
by having the clinical monitors assess the hospital course
and adverse events independently of the nurses and physi-
cians conducting the study .
The route and timing of heparin administration chosen for
this protocol could be questioned . The heparin protocol was
based on its nearly universal adaptation for clinical use,
largely because the combination of APSAC and heparin
successfully reduced mortality compared with conservative
care in the AIMS trial and because it was adopted in all other
clinical trials evaluating APSAC (26,27,39-41) . Alternative
heparin regimens could have ranged from immediate intra-
venous heparin with a bolus to delayed subcutaneous hepa-
rin. Recent preliminary data suggest that reperfusion may be
hastened with a bolus of heparin with streptokinase, but
within 2 to 3 h an effect on patency is not detectable (Coe J,
personal communication, November 1992) . Although an-
tithrombin therapy is important in preventing recurrent
thrombotic occlusions after myocardial infarction, heparin
as a specific agent has several limitations . Of most impor-
tance, the residual thrombus contains active thrombin bound
to fibrin, which is not easily accessible to the large heparin
antithrombin III complex
. Furthermore, the platelet-rich
arterial thrombus releases platelet factor 4 . Both platelet
factor 4 and the fibrin II monomer, which is formed by the
action of thrombin on fibrinogen, inhibit heparin (49-51) .
Thus, different antithrombin agents used after APSAC may
have resulted in different outcomes . In addition, the aPTT
measurements were not performed at a core laboratory ;
thus, these measurements may reflect site to site variability .
Another limitation was the timing of the angiogram . We
chose predischarge angiography because of our belief that
sustained infarct-related artery patency is the critical issue
(52)
. If important differences in early patency were not
detected because of the timing of angiography, they should
JACC Vol. 23, No. I
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have been reflected by either better early clinical outcome or
improved left ventricular function . We found evidence for
neither in this study in the group assigned to routine admin-
istration of heparin . Finally, there may be select subsets of
patients who could benefit from heparin therapy (i .e ., pa-
tients with mobile left ventricular thrombi or previous em-
bolic events), which was not demonstrated in our study
because of limited power.
Conclusions. The current study provides evidence that
the administration of intravenous heparin after APSAC
therapy should not be routinely recommended . The longer
half-life, systemic fibrinolytic activity, antiplatelet proper-
ties, as well as the viscosity-reducing properties of APSAC
compared with other thrombolytic regimens, may protect
the patient from reocclusion, particularly in the Ist 24 h after
thrombolysis . thus making heparin administration unneces-
sary. Ohman et al . (53) found that most reocclusions after
thrombolytic therapy occur within the I st 12 to 24 h (53) . and
the results of the National Heart Foundation of Australia
trial (11) suggest that the most important window for an
antithrombotic effect to prevent reocclusion is within the 1st
24 h, when the primary effects of APSAC persist (11) . Given
that heparin did not reduce ischemia or the presence of
angiographic patency and was associated with higher bleed-
ing and transfusion rates, there is little evidence from our
trial to support its use after APSAC . Thus, our findings
suggest that the routine addition of heparin to a regimen of
325 mg of aspirin after APSAC therapy, as currently recom-
mended, may not be warranted .
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